• slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • 20
    10/17
    NEWS
    Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics...
    Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A...
  • PRESS RELEASE
    Chiesi is the first Italian pharmaceutical Company for investments in Research...
    The 2017 edition of the EU Industrial R & D Investment Scoreboard of the European Commission places Chiesi Group at the top...